Neoadjuvant chemotherapy for the treatment of muscle-invasive bladder cancer: Argument in favor

Nature Clinical Practice Urology

Volumn 5, Issue 9, 2008, Pages 484-485

  Gallagher, David J ^a   Bajorin, Dean F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; BLADDER CANCER; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CYSTECTOMY; DISEASE FREE SURVIVAL; DRUG EFFICACY; HUMAN; MORBIDITY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROGNOSIS; SURGICAL MORTALITY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; HUMANS; MUSCLE NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; PREOPERATIVE CARE; URINARY BLADDER NEOPLASMS;

EID: 51549113350     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro1147     Document Type: Article

References (10)

1. Grossman HB et al. (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349: 859-866
2. Mieog JS et al. (2007) Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 94: 1189-1200
3. Hall RR (2002) Updated results of a randomized controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle invasive bladder cancer [abstract #710]. Proc Am Soc Clin Oncol 21: A710
4. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data. Eur Urol 48: 202-205
5. David KA et al. (2007) Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: A report from the National Cancer Data Base. J Urol 178: 451-454
6. Miles BJ and Eigl BJ (2008) Do Clinical Practice Guidelines (CPG) change clinical practice? An analysis of CPG impact on referral and treatment patterns for neoadjuvant chemotherapy in bladder cancer [abstract #295]. Presented at the ASCO 2008 Genitourinary Cancers Symposium: 2008 February 14-16, San Francisco, CA, USA
7. von der Maase H et al. (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18 3068-3077
8. Dash A et al. (2007) Efficacy of neo-adjuvant gemcitabine plus cisplatin (GC) in muscle-invasive urothelial cancer (UC) [abstract #5077]. J Clin Oncol 25 (Suppl 18S): A5077
9. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Adjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis of individual patient data. Eur Urol 48: 189-199
10. Dotan ZA et al. (2005) Optimal combined modality treatment improves outcome of locally advanced bladder cancer: Analysis of SWOG 8710 [abstract #4531]. J Clin Oncol 23 (Suppl 16S): A4531